Background Based on the AJCC seventh TNM classification, T1 intraglandular tumors are subdivided into T1a (≤10 mm) and T1b (11-20 mm), but the differences in prognosis remain controversial. The present study aimed to determine the clinicopathological features and outcomes of T1a and T1b patients. Methods A retrospective study of 2518 T1 patients, including 1840 T1a (73 %) and 678 (27 %) T1b patients who underwent surgery for PTC from 1978 to 2014, was conducted. In patients with a preoperative or operative diagnosis of PTC, a total thyroidectomy (TT) with prophylactic (macroscopically N0) or therapeutic (evident N1) lymph node dissection (LND) was performed. Other patients had a TT or partial thyroidectomy without LND. The mean follow-up time was 8.9 ± 8.8 years (median, 6.5 years; range, 1-36.4 years). Results A TT was performed in 2273 patients (90 %), including 1184 (52 %) with LND. Other patients (n = 245) had a single lobectomy with isthmectomy. Multifocality, bilaterality, number of tumors, sum of the largest size of all foci, vascular invasion, and (in patients with LND) LN metastases were significantly more frequent in T1b than in T1a patients. Of the 1184 patients with LND, 278 had LN metastases (N1, 23 %), including 136/680 T1a (20 %) and 142/504 (28 %) T1b patients (p = 0.002). These LN metastases were diagnosed after a prophylactic LND in 86/609 T1a (14 %) and 93/440 T1b (21 %) patients (p = 0.001). Recurrences were more frequent in T1b (n = 26, 3.8 %) than in T1a patients (n = 35, 1.9 %, p = 0.005). In the multivariate analysis, independent prognostic factors for recurrence in both groups were the number of tumors, the sum of the largest size of all foci and, in patients who had LND, LN metastases and extranodal extension. For N0-x patients, the recurrence rate was significantly higher in the T1b than in the T1a group (2.4 vs. 0.9 %, respectively, p = 0.005), although this rate was similar in N1 patients (16.2 % for T1a and 9.2 % for T1b patients, p = 0.1).
Introduction
Papillary thyroid cancers (PTCs) typically have an excellent prognosis, with an overall 10-year survival rate above 90 %. More than 80 % of thyroid cancers are attributed to small PTCs (defined as tumors ≤20 mm) [1] . Although most small PTCs have an indolent clinical course, several independent prognostic pejorative factors have been identified such as age >45 years, extrathyroidal extension, and lymph node (LN) and distant metastases. A large database study [2] concluded that tumors >10 mm have a higher recurrence rate than do PTCs ≤10 mm and require more extensive thyroid surgery. Consequently, the seventh edition of the AJCC pTNM staging system [3] subdivided the T1 category of intraglandular tumors into T1a (≤10 mm) and T1b (11-20 mm) , and the 2015 American Thyroid Association guidelines [4] recommended different therapeutic management for these two subgroups of PTC: a single lobectomy for T1a (unless there are clear indications to remove the contralateral lobe), a total thyroidectomy for T1b tumors, and post-surgical radioiodine therapy for T1bN0-x (N0 or Nx) with aggressive histology and for all T1 PTC with LN metastasis (N1).
However, the prognostic value of a 10-mm cutoff in maximum diameter remains controversial. Although it is well accepted that the recurrence rate closely correlates with a tumor size >20 mm in PTC without preoperatively detected node metastasis [5] , several studies have reported no difference in prognosis for small PTC tumors between 1 to 10 and 11 to 20 mm [6] [7] [8] . The aim of our study was to compare the clinicopathological features of T1a and T1b PTCs, excluding tumors with extrathyroidal extension, and to investigate the risk of recurrence of these two subgroups.
Patients and methods
A retrospective study of 2518 consecutive patients who underwent surgery for T1 PTCs at our institution from January 1978 to December 2014 was conducted. Primary tumors ≤20 mm with extrathyroidal extension (T3) were excluded from the study. Each patient underwent a systematic preoperative neck ultrasound (US). In patients with a preoperative (positive cytology) or operative (frozen section) diagnosis of thyroid carcinoma and a clinically negative nodal disease, we performed a total thyroidectomy with a prophylactic central (level VI) and lateral (levels III and IV, and level II if the cancer was located in the upper third of the thyroid lobe) lymph node dissection (LND) [9] on the side of the largest primary thyroid tumor. A therapeutic LND was performed in patients with clinically evident positive LN based on physical examination, neck US, or cytology. The remaining patients with a PTC diagnosed only on definitive pathology of thyroid resection had no LND (Nx). If PTC was identified by definitive pathology of a partial thyroid resection, complete thyroidectomy with ipsilateral neck dissection (central and lateral) was performed for T1b tumors only.
We collected patient demographic data (age, sex, and BMI). The following data were obtained from pathological examination: tumor size, number of tumors, sum of the largest size of all foci, multifocality and bilaterality, vascular invasion, number of resected LNs, number of LN metastases, and extranodal extension of positive LNs. During the postoperative course, indirect laryngoscopy was performed in patients with dyspnea, hoarseness, or loss of voice quality.
When recurrent laryngeal nerve (RLN) palsy was diagnosed, a trial of speech therapy was started during the first week and continued over several months for a course of 30 treatments. RLN palsy was considered permanent if there was no proof of recovery using laryngoscopy within 6 months of operation. Serum calcium concentration was assessed on postoperative day 1 and repeated on postoperative day 2 if the first result was <2 mmol/L. Symptomatic hypocalcemia was defined as a serum calcium level <2 mmol/L with overt manifestations, such as anxiety, carpopedal spasms, or tingling or numbness of the extremities. Hypoparathyroidism was considered permanent if the patient required oral calcium supplements and vitamin D for 6 months or more with a plasma parathyroid hormone level <29.4 pmol/L. Postoperative use of radioiodine ablation was also recorded. This treatment was administered for every T1b, every N1 patient, and any T1a with adverse features (vascular invasion; sum of the largest size of all foci >10 mm; or aggressive histologic subtypes, such as tall-cells, solid, columnar, oncocytic, or diffuse sclerosing variant). Radioiodine ablation was administered after withdrawing thyroid hormones for 1 month or (since 2010) with the use of recombinant human thyrotropin (r-TSH) in the lower-risk patient group. The radioactive 131 I dose administered was 3.7 GBq systematically until August 2012. Beginning in September 2012, we administered 1.1 GBq under r-TSH for PTC patients with a low or intermediate risk of recurrence (T1a and T1b excluding aggressive histologic subtypes of PTC).
Follow-up information was obtained from a database of patient medical records. A standardized procedure was used for patient follow-ups, including check-ups under thyroidstimulating hormone (TSH) stimulation at 6, 12 months, and annually thereafter. After 7 years of follow-up, periodic correspondence with patients or their referring physicians was designed to occur every 3 years. Physical examinations, neck US, and serum thyroglobulin (Tg) measurements after stimulation or under suppressive treatment were routinely performed during the follow-ups.
Events were analyzed retrospectively. Events that were considered recurrent included the following: locoregional recurrence defined as a thyroid bed, soft tissue, or cervical lymph node recurrence of PTC. The diagnosis of locoregional recurrence was assessed by histological analysis at surgery, by fine-needle aspiration biopsy or by 131 I cervical uptake anywhere in the neck after a 131 I diagnostic (11.1 MBq) or therapeutic (3.7 GBq) dose. In addition, patients with isolated and repeatedly elevated serum thyroglobulin levels (>10 ng/ml after T4 withdrawal) that justified the administration of a second therapeutic dose of 131 I and patients with distant metastases assessed by cytological or histological analysis or by iodine uptake after diagnostic or therapeutic scintigraphy were also considered to have recurrent disease.
Statistical analysis
Data analysis was performed using SPSS (version 21, IBM Corporation, Armonk, NY). Statistical analysis of the differences between clinical and histological variables between groups was conducted by chi-square tests or Fisher's exact test as appropriate. The Mann-Whitney U test was used to compare continuous variables, as we could not assume a normal distribution because of the relatively small numbers. A p value less than 0.05 was regarded as significant. A univariate logistic regression was used to estimate the relationship between recurrence and the following variables: patient sex, age, BMI, number of tumors (multifocality, bilaterality), sum of the largest foci sizes, vascular invasion, and LN metastases. We performed a Cox regression multivariate analysis that included the predictive factors that had a significant relationship with recurrence in the univariate analysis; odds ratios (ORs) were estimated by the use of an unconditional logistic regression model. Disease-free survival was calculated using the Kaplan-Meier method and log-rank test.
Results

Characteristics of the study cohort
During the study period, 2518 patients underwent surgery for T1 PTCs, including 1840 (73 %) T1a and 678 T1b tumors. Indication for surgery was a preoperative diagnosis of PTC in 547 patients (22 %) (positive ultrasound-guided fine-needle aspiration cytology). An additional group of 637 patients (25 %) had a positive frozen section during surgery and received, like the previous group, a total thyroidectomy with LND. For the remaining patients (n = 1334; 53 %), PTC was diagnosed only on final pathology of a thyroid specimen, including 1160 T1a (63 % of all T1a patients) and 174 T1b (26 %) (p < 0.0001) ( Table 1) . Of the entire cohort, 2273 patients had a total thyroidectomy, including 1184 with LND. Other patients (n = 245) had a single lobectomy with isthmectomy.
The results of recurrent laryngeal nerve palsies and postoperative hypoparathyroidism are summarized in Table 1 . The permanent complication rate was 3.2 % in T1a patients (n = 58) and 3.7 % in T1b patients (n = 25). We found no significant difference in the rate of permanent complications between patients with or without lymph node dissection (LND): 22/680 LND (3.2 %) vs. 36/1160 Nx (3.1 %) in the T1a group (p = 0.9) and 19/504 LND (3.8 %) vs. 6/174 Nx (3.4 %) in the T1b group (p = 0.8).
The pathological features of the T1 PTC patients are shown in Table 2 . The number of tumors (2.3 vs. 1.6) and the sum of the largest size of all foci (19 vs. 6 mm) were greater in T1b than in T1a patients (p < 0.0001), and vascular invasion (8 vs.
1 %), multifocality (45 vs. 29 %), and bilaterality (27 vs. 14 %) of the tumor were significantly more frequent in T1b than in T1a patients (p < 0.0001). T1b patients had a higher rate of LND than did T1a patients (74 vs. 37 %, p < 0.0001). In patients who had a LND (1184 patients), metastases to the lymph nodes (N1) were more frequent in T1b than in T1a patients (142/504 patients, 28 %, vs. 136/680 patients, 20 %, respectively, p = 0.002), and the number of involved LNs was greater in T1b than in T1a patients (median, 3 (1-23) vs. 1 (1-230, respectively, p = 0.001). Central and lateral LN metastases were significantly more frequent in the T1b group: 123 (24 %) and 73 (14 %), respectively, in T1b patients, 106 (16 %) and 57 (8 %), respectively, in T1a patients (p = 0.0001). Of the 130 N1b patients (57 T1a and 73 T1b), 49 (38 %) had isolated lateral LN metastasis (skip metastasis) (30 T1a and 19 T1b, p = 0.001).
Of the patients with a prophylactic LND (n = 1049), 179 had LN metastases (17 %), including 86/609 T1a (14 %) patients and 93/440 T1b (21 %) (p = 0.001). The lateral compartment (N1b) was involved in 61 (34 %) of these patients, including 22/86 T1a (26 %) and 39/93 T1b (42 %) patients (p = 0.02).
A total of 1248 patients (50 %) received radioiodine therapy, including 603 (33 %) T1a and 645 (95 %) T1b patients. There was no difference between T1a and T1b patients in terms of 131 I dose (mean, 3.7 ± 0.3 GBq vs. 3.5 ± 0.4 GBq, respectively).
Follow-up and oncologic outcomes
Postoperative follow-up ranged from 2 to 36.4 (median, 6.5) years. Recurrence was observed in 61 patients (2.4 %), including 35 T1a (1.9 %) and 26 T1b patients (3.8 %) (p = 0.005) ( Table 3 ). The median time from initial surgery to recurrence was similar in both groups: 1.6 years (range, 0.2-8.9 years) for T1b patients and 1.1 years (range, 0.2-12 years) for T1a patients (p = 0.5). Locoregional recurrence occurred in 45 patients (74 % of recurrences), all of whom underwent reoperative surgery. Other patients had distant metastases (n = 4) or elevated isolated serum thyroglobulin levels (n = 12) and were exclusively treated with repeated iodotherapy. Five patients (4 T1a and 1 T1b) died from distant metastases of PTC.
Of the N1 patients (n = 278), the recurrence rates were equivalent between T1a and T1b patients, with rates of 16.2 % (22/136) and 9.2 % (13/142), respectively (p = 0.1). These recurrence rates were higher than those found in N0 and Nx patients: 0.7 % (4/544) of T1a N0 (p < 0.001), 0.8 % (9/1160) of T1a Nx (p < 0.001), 1.4 % (5/362) of T1b N0 (p < 0.001), and 4.6 % (8/174) of T1b Nx patients (p = 0.1).
When the T1a N0-x and T1b N0-x patient subgroups were compared, we found a higher recurrence rate in the T1b N0-x group: 2.4 % (13/537) in the T1b N0-x vs. 0.9 % in the T1a N0-x group (16/1703) (p = 0.005). In patients who had no LND (Nx), T1b patients had a higher risk of recurrence than T1b N0 patients (4.6 vs. 1.4 %, respectively; p = 0.02), whereas no difference was observed in T1a patients (0.8 % for T1a Nx vs. 0.7 % for T1a N0; p = 0.8).
Within the groups of T1a and T1b patients, the univariate analysis revealed a significantly higher risk of recurrence relative to tumor size, multifocality, including number of tumors, sum of the largest size of all foci, lymph node metastases, and extranodal extension (Table 4) . Age >45 years, vascular invasion and distant metastases in T1a patients, and male gender and bilaterality in T1b patients were also significantly associated with recurrence. In the multivariate analysis, the number of tumors (OR = 1. The 5-year disease-free survival (DFS) was high but significantly different between the T1a and T1b patients (98.3 vs. 96.6 %, respectively; p = 0.01). A log-rank test showed that the DFS rate was significantly greater in the T1a than in the T1b group (p = 0.01) (Fig. 1) . Data are presented as n (%), mean ± SD or as median (range) FNAB fine-needle aspiration biopsy
Discussion
It is still unclear in the current literature whether T1a and T1b patients have similar prognoses and whether the therapeutic management of these patients should differ. In the present study, we report that the clinicopathological features and risk of recurrence are not similar between T1a and T1b patients, with a higher incidence of multifocality including the number of tumors, bilaterality, vascular invasion, and lymph node metastases in T1b patients and a poorer prognosis with an increased risk of recurrence and a lower DFS for T1b patients with a tumor >10 mm. We found a higher rate of incidentally diagnosed PTCs in T1a than in T1b patients (63 vs. 26 %, p < 0001). Because we performed a systematic LND in case of preoperative or operative diagnosis of PTC, LND was significantly more frequent in T1b than in T1a patients in our study. For patients with LND, T1b PTC had a significantly higher rate of LN metastases than did T1a PTC (28 vs. 20 %, p = 0.002). This finding is in agreement with the importance of tumor size, even in small PTC, as a strong predictive factor of LN metastases [10] . Reddy et al. [11] reported no difference in LN spread between tumors less than 1 cm and those between 1 and 2 cm; however, they only evaluated patients who were referred for radioiodine therapy, with an unusually high rate of LN metastases (45 %) for tumors <2 cm.
Several authors have already reported different clinicopathological features and outcomes for tumors ≤10 mm and those 11-20 mm, but they have usually included small tumors with extrathyroidal extension (ETE) and heterogeneous thyroid Data are presented as n (%), mean ± standard deviation or as median (range) LND lymph node dissection Fig. 1 Disease-free survival (DFS) curves of the T1a (n = 1840) and T1b (n = 678) patients carcinoma including follicular cancers [6, [10] [11] [12] [13] [14] . However, it is well-recognized that one of the most pejorative factors in the risk of PTC recurrence is the presence of ETE [10] . For example, Ito et al. [8] investigated the prognosis of 2638 patients with PTCs measuring 20 mm or less who did not have a massive ETE (T4), clinically apparent lymph nodes, or distant metastasis. They reported that the disease-free survival (DFS) was not affected by tumor size (≤10 vs. 11-20 mm); however, 21 % of their PTCs had a minimal ETE of the tumor (T3). Wang et al. [7] conducted the first study that was limited to small PTCs without ETE (T1a and T1b). They reported similar rates of recurrence in T1a and T1b patients (1.2 %) with a 5-year DFS that was identical for both groups (98.6 %, p = 0.2). However, the median follow-up was relatively short in this study (46 months), and the standard postoperative check-up procedure was not described. With a longer follow-up, we reported a twofold risk of recurrence in T1b patients when compared to T1a patients (3.8 vs. 1.9 %, respectively, p = 0.005). We therefore believe that these two categories of small PTC do not have similar outcomes and that the subdivision of the T1 category into T1a and T1b (AJCC staging seventh edition) seems to be justified.
A prophylactic LND remains controversial for T1 PTCs. Although it is useful in determining accurate PTC staging by estimating the risk stratification and by facilitating management of the disease, follow-up strategies, and postsurgical administration of 131 I [15, 16] , it is not recommended in the current guidelines [4, 17, 18] for clinically node-negative small PTCs. The rationale behind these guidelines is the lack of proven benefit of its long-term clinical outcome and the risk of surgical complications associated with central lymph node dissection, i.e., recurrent laryngeal nerve palsy and hypoparathyroidism. However, the present study demonstrated that our strategy of performing systematic prophylactic lymph node dissection was not responsible for a significant increase in the rate of postoperative complications. Moreover, prophylactic central and lateral LNDs revealed LN metastases in 17 % of T1 patients, including 21 % of T1b and 14 % of T1a patients. Machens et al. [14] analyzed the correlation between primary tumor size and risk of extrathyroidal extension, lymph node, and distant metastasis in 366 PTC and 134 follicular thyroid carcinomas (FTC). The cumulative risks increased linearly with increasing tumor diameter, even in small PTC <20 mm. They reported that the smallest size for developing extrathyroidal extension and lymph node metastases was 5 mm for PTC. They also showed that the cumulative risk of distant metastasis increased once the primary tumor size was 20 mm. However, in our study including 960 PTC with a primary tumor size less than 5 mm, 14.4 % of patients with LND had lymph node metastases (28/194). Furthermore, distant metastases were present in 11 T1 patients including 9 T1a patients. Consequently, we recommend a surgical strategy with systematic prophylactic lymph node dissection for all T1 PTC tumors, including for tumor sizes <5 mm.
Among the 1248 patients who had a radioiodine ablation in our institution (including 645 T1b and 603 T1a patients), 93 T1b (14 %) and 86 T1a patients (14 %) had LN metastasis discovered after a prophylactic LND. Moreover, if the prophylactic LND had been limited to the central compartment, 61 patients with lateral LN metastases (N1b) would not have been detected. We also found that the prognosis of T1b patients who did not undergo LND (Nx) was significantly poorer than it was for N0 patients and that LN metastases (N1) were also associated with a higher risk of recurrence than N0-x in the two subgroups of T1a and T1b patients. In the multivariate analysis, LN metastases and extranodal extension were found to contribute to the risk of recurrence in T1a and T1b patients. However, although these findings emphasize the utility of performing prophylactic central and lateral LND to assess an accurate staging of small PTC, we also report that it did not improve the prognosis of T1 patients and that similar results have been obtained in previous studies [8, 19] .
Although we analyzed a large cohort of consecutive T1 patients, our study has several limitations, including its retrospective nature. However, we believe that our homogeneous management of PTC patients, including surgical procedures with systematic prophylactic LND during the study period, overcomes the potential limitations of the study.
In conclusion, T1b patients have poorer clinicopathological features and increased risk of recurrence than T1a patients. A systematic prophylactic LND should be considered even in these small tumors to guide the indication for radioiodine therapy and to determine the intervals of post-surgical follow-up.
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